Activity of eribulin in patients with advanced liposarcoma demonstrated in a subgroup analysis from a randomized phase III study of eribulin versus dacarbazine
- George D. Demetri
- , Patrick Schöffski
- , Giovanni Grignani
- , Jean Yves Blay
- , Robert G. Maki
- , Brian A. Van Tine
- , Thierry Alcindor
- , Robin L. Jones
- , David R. D’Adamo
- , Matthew Guo
- , Sant Chawla
- Roy and Diana Vagelos Division of Biology & Biomedical Sciences (DBBS)
- Institute of Clinical and Translational Sciences (ICTS)
- Siteman Cancer Center
- Section of Medical Oncology
- Bursky Center for Human Immunology and Immunotherapy
- DBBS - Molecular Cell Biology
- DBBS - Molecular Genetics and Genomics
- DBBS - Cancer Biology
Research output: Contribution to journal › Article › peer-review
154
Link opens in a new tab
Scopus
citations